

# **NIH** funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 28 Mar 2022 (#12)

[Click on blue <u>hyperlink</u> for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit <a href="www.grants.nih.gov">www.grants.nih.gov</a> or <a href="www.grants.nih.

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: <u>cdevries@sun.ac.za</u> ● Stellenbosch Campus <u>lizelk@sun.ac.za</u>

## **Important Notices**

- Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office) not later than 31 March 2022. For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.
  - FMHS contact: cdevries@sun.ac.za
  - Stellenbosch Campus contact <u>lizelk@sun.ac.za</u>.

Link to the training: https://grants.nih.gov/grants/policy/coi/tutorial2018/story\_html5.html

NOT-NS-22-088 Notice of Intent to Publish a Funding Opportunity Announcement for Impact of the Microbiome Gut-Brain Axis on ADRD (R01 Clinical Trial Not Allowed). The National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA) intend to publish a Funding Opportunity Announcement (FOA) to solicit applications for basic and translational research on the impact of the microbiome gut-brain axis on Alzheimer's Disease Related Dementias (ADRD). While there is growing evidence that the microbiome is an important factor that contributes to overall health and a variety of diseases and disorders, the role of intestinal microbiota dysfunction in specific ADRDs has not been adequately addressed. This FOA will utilize the R01 (Clinical Trials Not Allowed) activity code. First Estimated Application Due Date: September 06, 2022

#### **Parent Announcements**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- PA-20-183 Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- <u>PA-20-196</u> NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## **Notice of Special Interest**

- NOT-CA-22-057 Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Stimulate or Strengthen Global Cancer Health Disparities Research. This Notice of Special Interest announces the continued availability of supplemental funding to stimulate interest and promote the inclusion of global populations [populations outside of the United States (U.S.), particularly those in low- and middle-income countries (LMICs)], to enhance and/or accelerate the progress in understanding and developing interventions to reduce cancer health disparities in the U.S. and globally. This administrative supplement is designed to support investigators with active NCI awards to include global populations in their research projects thereby advancing cancer health disparity research. The parent award does not need to have a cancer health disparities research aspect or question included as part of their original scientific aims. However, the request for supplemental funding must propose to enhance the already funded research project/program by incorporating a cancer health disparities aspect, and by including a global population. The budget should not exceed \$200,000 in total costs. The application budget is limited to 1 year only. The project and budget periods must be within the currently approved project period for the existing parent award. Application Due Date: Submissions must be received by May 24, 2022, at 5:00 PM local time of applicant organization for FY 2022 funding.
- NOT-EB-22-006 Notice of Special Interest (NOSI): Technological Innovations for Advancing Clinical SPECT Imaging. The purpose of this Notice is to inform potential applicants to the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in developing nuclear medicine imaging technologies to achieve more cost-efficient clinical Single-Photon Emission Computerized Tomography (SPECT) applications. This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through May 8, 2024. Applicants planning to submit an application in response to this NOSI are strongly encouraged to contact the Scientific/Research Contact listed, well in advance of the application due date to discuss their proposed research/aims.
- NOT-MH-22-170 Notice of Special Interest (NOSI): Research using implementation science to support the delivery of evidence-based practices in community-based mental or general medical healthcare settings. This Notice of Special Interest (NOSI) highlights interest in mental health services and implementation science research to support the adoption and sustainability of evidence-based practices (EBPs) in community-based settings that deliver care to people with mental illness. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) Certified Community Behavioral Health Clinic-Expansion (CCBHC-E) grant program. The National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), and the Substance Abuse and Mental Health Services Administration (SAMHSA) recognize that effective research-practice partnerships are crucial for identifying salient research questions and developing and testing realistic, adoptable, scalable, and sustainable implementation strategies that promote continuously improving mental and behavioral health care. To be competitive, researchers must partner with healthcare delivery organizations and/or organizations charged to deliver implementation support to healthcare delivery organizations. This notice applies to due dates on or after May 7, 2022 and subsequent receipt dates through May 8, 2025.

## **Funding Opportunity Announcements (FOA)**

## 1. Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: PAR-22-076

Application Page 27 2022 through to May 27 2025 Applications of applicatio

Application Due Date: June 17, 2022 through to May 07, 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.

Type: UG3/UH3

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Up to 2 years for the UG3; up to 5 years for the UH3. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request \$500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

#### 2. Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date Hyperlink: RFA-CA-22-021

Type: R21

Type: U24

Application Due Date: June 14, 2022; November 17, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, the emphasis of this FOA is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research. To be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Projects with a significant level of data generation and/or data analysis will not be considered responsive to this funding opportunity.

Budget: NCI intends to fund an estimate of 5 awards, corresponding to a total of \$1,020,000, for fiscal year 2023. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

### 3. Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date Hyperlink: RFA-CA-22-022 Type: U01

Application Due Date: June 14, 2022; November 17, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

Budget: NCI intends to commit \$2,250,000 in FY 2022 to fund 5-6 awards. Budgets are limited to \$300,000 Direct Costs (excluding consortium F&A) per year. The maximum project period is three years.

#### 4. Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: RFA-CA-22-023 **Application Due Date:** June 14, 2022; November 17, 2022Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. To be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be

Budget: NCI intends to fund an estimate of 4 awards, corresponding to a total of \$3.6M, for fiscal year 2023. Budgets are limited to \$600,000 Direct Costs (excluding consortium F&A) per year.

included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the

#### 5. Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

companion FOAs listed above.

Hyperlink: RFA-CA-22-024 Type: U24

Application Due Date: June 14, 2022; November 17, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.

Budget: NCI intends to fund an estimate of 1 award, corresponding to a total of \$1,130,000, for fiscal year 2023. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

#### 6. BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date Hyperlink: RFA-MH-22-220 Type: R01

Application Due Date: June 10, 2022 through to June 07, 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain. As part of programs of building the informatics infrastructure for the BRAIN Initiative, the FOA supports several different, but related activities. These include modifying existing analysis and visualization tools to deal with BRAIN Initiative data and integrating different types of BRAIN Initiative datasets. Proposing the development of new tools to deal with BRAIN Initiative data is also permitted. The tools supported under this FOA will make use of relevant data standards and will be built so that they can be integrated into the data repositories, both of which are created in awards under the other FOAs of the BRAIN initiative informatics program. The tools must be user-friendly in accessing and analyzing data from appropriate data archives, and should analyze/visualize data without requiring users to download data. The tools should also allow data to be combined for analysis/visualization from multiple locations.

**Budget:** NIMH and partner <u>components</u> intend to commit an estimated total of \$4 million to fund 4-7 awards for each round of funding. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

e: <u>cdevries@sun.ac.za</u> | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street

Enquiries: *Lizél* e: <u>lizelk@sun.ac.za</u> | t: +27 21 808 2105